123 related articles for article (PubMed ID: 37245332)
21. Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation.
Jeong SH; Moon JH; Kim JS; Yang DH; Park Y; Cho SG; Kwak JY; Eom HS; Won JH; Hong JS; Oh SY; Lee HS; Kim SJ
Ann Hematol; 2015 Apr; 94(4):617-25. PubMed ID: 25465233
[TBL] [Abstract][Full Text] [Related]
22. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
[TBL] [Abstract][Full Text] [Related]
23. Hyper-CVAD regimen in routine management of adult acute lymphoblastic leukemia: a retrospective multicenter study.
Buyukasik Y; Acar K; Kelkitli E; Uz B; Serefhanoglu S; Ozdemir E; Pamukcuoglu M; Atay H; Bektas O; Sucak GT; Turgut M; Aksu S; Yagci M; Sayınalp N; Ozcebe OI; Goker H; Haznedaroglu IC
Acta Haematol; 2013; 130(3):199-205. PubMed ID: 23797290
[TBL] [Abstract][Full Text] [Related]
24. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Sasaki K; Kantarjian HM; Morita K; Short NJ; Konopleva M; Jain N; Ravandi F; Garcia-Manero G; Wang S; Khoury JD; Jorgensen JL; Champlin RE; Khouri IF; Kebriaei P; Schroeder HM; Khouri M; Garris R; Takahashi K; O'Brien SM; Jabbour EJ
Cancer; 2021 Sep; 127(18):3381-3389. PubMed ID: 34138471
[TBL] [Abstract][Full Text] [Related]
25. [A clinical report on modified Hyper-CVAD regimen in patients with lymphoblastic lymphoma].
Shi W; Shi YK; He XH; Zhou SY; Dong M; Zhang CG; Yang JL; Liu P; Qin Y; Yang S; Gui L
Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):978-81. PubMed ID: 20646648
[TBL] [Abstract][Full Text] [Related]
26. Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
Othman T; Moskoff BN; Ho G; Tenold ME; Azenkot T; Krackeler ML; Fisch SC; Potter LA; Kaesberg PR; Welborn JL; Wun T; Esteghamat NS; Hoeg RT; Rosenberg AS; Abedi M; Tuscano JM; Jonas BA
Leuk Res; 2022 Aug; 119():106885. PubMed ID: 35738024
[TBL] [Abstract][Full Text] [Related]
27. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.
Thomas D; O'Brien S; Faderl S; Ravandi F; Jabbour E; Pierce S; Cortes J; Kantarjian H
Cancer; 2010 Oct; 116(19):4580-9. PubMed ID: 20572037
[TBL] [Abstract][Full Text] [Related]
28. Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia.
Zarling LC; Stevenson PA; Soma LA; Martino CH; Percival MM; Halpern AB; Ghiuzeli CM; Becker PS; Oehler VG; Cooper JP; Orozco JJ; Hendrie PC; Walter RB; Estey EH; Cassaday RD
Eur J Haematol; 2023 Dec; 111(6):863-871. PubMed ID: 37670560
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
[TBL] [Abstract][Full Text] [Related]
30. The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia.
Jabbour E; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):63-65. PubMed ID: 33191168
[No Abstract] [Full Text] [Related]
31. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
Benjamini O; Dumlao TL; Kantarjian H; O'Brien S; Garcia-Manero G; Faderl S; Jorgensen J; Luthra R; Garris R; Thomas D; Kebriaei P; Champlin R; Jabbour E; Burger J; Cortes J; Ravandi F
Am J Hematol; 2014 Mar; 89(3):282-7. PubMed ID: 24779033
[TBL] [Abstract][Full Text] [Related]
32. Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial.
Testi AM; Canichella M; Vitale A; Piciocchi A; Guarini A; Starza ID; Cavalli M; De Propris MS; Messina M; Elia L; Moleti ML; Martino B; Luppi M; D'Aloisio M; Candoni A; Conter V; Fazi P; Vignetti M; Chiaretti S; Foà R
Am J Hematol; 2021 Mar; 96(3):292-301. PubMed ID: 33284999
[TBL] [Abstract][Full Text] [Related]
33. Outcome of young adult patients with very-high-risk acute lymphoblastic leukemia treated with pediatric-type chemotherapy - a single institute experience.
Cheng CN; Li SS; Hsu YT; Chen YP; Chen TY; Chen JS
J Formos Med Assoc; 2022 Mar; 121(3):694-702. PubMed ID: 34340890
[TBL] [Abstract][Full Text] [Related]
34. Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy.
Brady V; Thosani S; Zhou S; Bassett R; Busaidy NL; Lavis V
Diabetes Technol Ther; 2014 Dec; 16(12):874-9. PubMed ID: 25321387
[TBL] [Abstract][Full Text] [Related]
35. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
Thomas DA; O'Brien S; Cortes J; Giles FJ; Faderl S; Verstovsek S; Ferrajoli A; Koller C; Beran M; Pierce S; Ha CS; Cabanillas F; Keating MJ; Kantarjian H
Blood; 2004 Sep; 104(6):1624-30. PubMed ID: 15178574
[TBL] [Abstract][Full Text] [Related]
36. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
Jabbour E; Short NJ; Ravandi F; Huang X; Daver N; DiNardo CD; Konopleva M; Pemmaraju N; Wierda W; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Khoury JD; Jorgensen J; Jain N; Alvarez J; O'Brien S; Kantarjian H
Lancet Haematol; 2018 Dec; 5(12):e618-e627. PubMed ID: 30501869
[TBL] [Abstract][Full Text] [Related]
37. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.
O'Brien S; Thomas DA; Ravandi F; Faderl S; Pierce S; Kantarjian H
Cancer; 2008 Oct; 113(8):2097-101. PubMed ID: 18720356
[TBL] [Abstract][Full Text] [Related]
38. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian HM; O'Brien S; Smith TL; Cortes J; Giles FJ; Beran M; Pierce S; Huh Y; Andreeff M; Koller C; Ha CS; Keating MJ; Murphy S; Freireich EJ
J Clin Oncol; 2000 Feb; 18(3):547-61. PubMed ID: 10653870
[TBL] [Abstract][Full Text] [Related]
39. Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults.
Oh I; Hatano K; Ikeda T; Toda Y; Minakata D; Kawaguchi S; Morita K; Yamamoto C; Ashizawa M; Sato K; Kameda K; Gomyo A; Misaki Y; Kawamura S; Kimura S; Kobayashi H; Sato H; Nakasone H; Ohmine K; Fujiwara S; Kako S; Kanda Y
Leuk Res; 2024 Feb; 137():107438. PubMed ID: 38278044
[No Abstract] [Full Text] [Related]
40. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
Jabbour E; Ravandi F; Kebriaei P; Huang X; Short NJ; Thomas D; Sasaki K; Rytting M; Jain N; Konopleva M; Garcia-Manero G; Champlin R; Marin D; Kadia T; Cortes J; Estrov Z; Takahashi K; Patel Y; Khouri MR; Jacob J; Garris R; O'Brien S; Kantarjian H
JAMA Oncol; 2018 Feb; 4(2):230-234. PubMed ID: 28859185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]